Patient records
Name: Sarah
Age: 32
Nationality: Australia
Diagnosis: Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), non-germinal center type (non-GCB), CD19 positive, relapsed after autologous stem cell transplantation.
Treatment Hospital: Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Tianjin)
In the field of cancer treatment, CAR-T cell therapy is hailed as "living medicine," bringing hope of a cure to patients with relapsed or refractory hematological malignancies. However, this hope comes with a hurdle: in the West, it is prohibitively expensive, and the waiting time for its preparation is enormous. Sarah's story tells how she overcame this hurdle and found an accessible "cure" in China.
1. "I might not be able to wait any longer."
Sarah, a young Australian lawyer, was diagnosed with diffuse large B-cell lymphoma two years ago. After standard first-line R-CHOP chemotherapy, she achieved complete remission. However, the lymphoma relapsed a year later. She underwent second-line salvage chemotherapy and an autologous stem cell transplant, but the tumor relapsed again just six months after the transplant. Her doctor told her that the only potentially curative option was CAR-T cell therapy, but in Australia, this is not only expensive but also involves a waiting period of several months.
“Doctor, I might not be able to wait any longer.” Sarah looked at the increasingly enlarged lymph nodes in her neck, her heart filled with fear. Through the international lymphoma support community, she learned that China is not only one of the countries with the most CAR-T clinical trials in the world, but also has several commercially available CAR-T products approved, with prices far lower than in the West and shorter preparation cycles.
2. Finding an accessible "Chinese solution" in the face of the dual barriers of "time" and "money".
Sarah's request was very direct: "I want to go to China to get CAR-T surgery, the sooner the better. Can you help me arrange it?"
Precise matching and treatment plan planning. After reviewing her pathology report, we confirmed that her tumor cells were CD19 positive, meeting the indications for CD19 CAR-T therapy. We matched her with one of the most experienced centers in China in the field of commercial CAR-T therapy— the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Tianjin). During the remote consultation, the experts planned a comprehensive treatment plan for her: first, bridging chemotherapy to control the disease, then lymphocyte ablation chemotherapy, and finally, CD19 CAR-T cell infusion.
Close monitoring during and after treatment. Upon Sarah's arrival in China, we initiated a "CAR-T fast track" for her. Our coordinator assisted her throughout the entire process, from cell collection and bridging therapy to CAR-T infusion. During the crucial two weeks following the CAR-T infusion, the coordinator recorded her vital signs daily, closely monitored for early signs of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and promptly reported to the medical team. Post-treatment, we established a "CAR-T Post-operative Long-Term Follow-up Record" for her, with the core task of monitoring minimal residual disease (MRD). We coordinated with hospitals in Australia to conduct monthly peripheral blood ctDNA tests for her, and shared the results with Chinese experts. If MRD turned positive, we immediately activated the alert mechanism to assist experts in deciding whether maintenance therapy or a second infusion was necessary.
3. Therapeutic Effects and Insights
One month after the CAR-T infusion, Sarah's PET-CT scan showed complete metabolic remission of the tumor (Deauville score of 1), marking her second complete remission. In a message to us, she said, "Thank you for helping me overcome the barriers of exorbitant costs and long waits. You showed me that the hope of a cure is within reach. When I returned to Sydney and walked back into my law firm, I felt like I was reborn."